The dynamic methylation and regulatable splicing variants of PARK7 suggest its potential as a subtype-specific therapeutic target, and the discoveries made in our study offer potential directions for developing personalized treatment strategies targeting specific BC subgroups, thereby advancing the application of precision medicine in the field of breast cancer. Here, PARK7 is linked to breast carcinoma.